Nonclinical Regulatory Services

Strategic Nonclinical Guidance for Rare Disease Programs

RareMoon provides expert nonclinical regulatory strategy tailored to the unique challenges of rare disease and advanced therapy drug development. Our team works closely with sponsors to navigate the complex nonclinical landscape, ensuring that preclinical programs are designed to support successful IND and CTA submissions.

From toxicology and pharmacology study design to nonclinical data package optimization, we help sponsors build scientifically robust programs that meet FDA, EMA, and global regulatory expectations. Our deep experience with gene therapies, biologics, and small molecules in the rare disease space ensures that nonclinical strategies are aligned with the latest regulatory guidance and precedent.

Related Services